BACKGROUND: Despite its functional importance in various fundamental bioprocesses, studies of N 6 -methyladenosine (m6A) in the heart are lacking. Here, we show that the FTO (fat mass and obesity-associated protein), an m6A demethylase, plays a critical role in cardiac contractile function during homeostasis, remodeling, and regeneration.
C urrent therapeutic approaches have resulted in limited success in treating ischemic heart disease and mitigating postischemic adverse cardiac remodeling. Therefore, new concepts for myocardial repair and regeneration that improve cardiac function have to be developed. Although several transcription factors and transcriptional coactivators have been studied in the context of heart failure, posttranscriptional regulations of cardiac mRNAs that can affect the expression of key proteins and cardiac function remain largely unexplored. Earlier studies have shown that (1) protein expression in failing human hearts does not correlate with the corresponding mRNA abundance, 1,2 and (2) nuclear and cytosolic mRNA levels do not correlate in cardiac myocytes, 3 suggesting a role for altered posttranscriptional RNA modifications in regulating protein expression in failing hearts. Therefore, we investigated epitranscriptomic regulations underlying cardiac remodeling and found a predominant but previously unidentified mechanism contributing to heart failure via dysregulated RNA modifications.
Even though epitranscriptomic mechanisms are under intense study, our knowledge about their biological function, especially in healthy tissues and organs and under pathological conditions, are limited. Recent findings suggest that the most abundant internal chemical modification in RNA, N 6 -methyladenosine (m6A), is a critical regulator of mRNA stability, protein expression, and several other cellular processes. [4] [5] [6] [7] Although dysregulated m6A has been linked to various types of cancers 8, 9 and brain diseases, 10 its role in cardiac homeostasis and failure has not been studied.
Several recent discoveries suggest that epitranscriptomic mRNA modifications are reversible and dynamically regulated with dedicated writers (methyltransferases) that catalyze addition of m6A (METTL3, METTL4, METTL14, and WTAP) and dedicated erasers (demethylases) that catalyze removal of m6A (FTO, ALKBH5) from mRNA. 11 The FTO (fat mass and obesity-associated protein) has been found to have a key role in regulating transcriptome-wide m6A modification in mRNA 4, 12 and is one of the m6A regulators that has been associated with metabolic disorders such as diabetes mellitus and obesity. 13, 14 Although FTO is expressed ubiquitously, cardiac ventricular levels are high in addition to brain and liver tissues in human embryos. 15 It is interesting to note that FTO has been implicated in cardiac defects including hypertrophic cardiomyopathy, ventricular septal and atrioventricular defects, 15 arrhythmias, 16 and coronary heart disease, 17 suggesting an important role for FTO in ischemic heart failure.
So far, m6A function in physiological and biological processes has been investigated. However, studies of m6A under pathological conditions, especially in tissues and organs, are limited. Moreover, FTO-dependent m6A demethylation and its role in cardiac protein expression and contractility in healthy and failing myocardium have not been addressed. Using clinical human samples, preclinical pig and mouse models of heart failure, and primary cardiomyocyte cell culture, we have investigated the physiological and pathological role of FTO-dependent m6A epitranscriptome in cardiac homeostasis, remodeling, and repair. We present evidence that m6A in RNA is dysregulated in failing hearts and that FTO-dependent m6A plays a significant role in pathomechanisms of heart failure at the molecular (mRNA degradation and protein expression), cellular, and organ (cardiomyocyte and cardiac function) levels. Moreover, we show that FTO gene delivery attenuates the ischemia-induced cardiac remodeling demonstrating the therapeutic potential of FTO in the treatment of heart failure. Mechanistically, FTO selectively demethylates calcium handling and contractile transcripts, preventing their degradation and regulating their protein
Clinical Perspective
What Is New?
• We discovered that N 6 -methyladenosine (m6A), one of the most prevalent and functionally relevant RNA modifications, is increased in failing mammalian hearts and in hypoxic cardiomyocytes.
• Our research suggests that dysregulation of m6A is an important hallmark of mammalian heart failure.
• Expression of an m6A demethylase, FTO (fat-mass and obesity associated protein), decreases in failing hearts, leading to an aberrant increase in transcriptome-wide m6A and decreasing cardiomyocyte contractile function.
• Improving expression of FTO in ischemic mouse hearts attenuates ischemia-induced increase in m6A and decrease in cardiac contractile function. FTO selectively demethylates cardiac contractile transcripts, thus preventing their degradation and improving their protein expression under ischemia.
What Are the Clinical Implications?
• Our study demonstrates the functional importance of FTO-dependent cardiac m6A methylome in cardiac contraction during heart failure and provides a novel mechanistic insight into the therapeutic mechanisms of FTO.
• Our data provide proof of principle that FTO plays an important functional role in cardiac homeostasis and myocardial repair and that targeting FTO signaling may represent a promising therapeutic strategy to treat heart failure.
• Our findings on the dynamic nature of the cardiac m6A-epitranscriptome lead to deeper understanding of the mechanism of cardiac remodeling on the one hand and innovative therapeutic interventions on the other. 
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expression in the failing heart. Our results have uncovered a novel function for FTO-regulated m6A mechanisms in cardiac remodeling and repair. We also establish that targeting cardiac epitranscriptome via FTO can be an effective therapeutic strategy for heart failure.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design
Human left ventricular (LV) tissues were obtained from deidentified, postmortem failing (with diagnosed cardiomyopathy) and nonfailing (with no history of cardiomyopathy and noncardiac related death) hearts from National Disease Research Interchange. No human subjects were involved. The Mount Sinai Institutional Review Board approved procurement of human tissue samples from the National Disease Research Interchange, and all usage was done as per Mount Sinai-approved guidelines. Both male and female tissues were used from human failing and nonfailing hearts. Similarly, for all animal experiments, both male and female mice (c57Bl6) and rats (Sprague-Dawley rats for cardiomyocyte isolation) were used. All the experimental protocols are in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and standards of US regulatory agencies. All treatments and measurements of cardiomyocyte (IonOptix) and cardiac (echocardiography) function were performed in a blinded manner. To investigate m6A in cardiac transcriptome, we developed novel methods such as m6A quantification in total or polyadenosine (polyA + ) RNA and methylated (m6A) RNA immunoprecipitation and sequencing (MeRIP-seq) in RNA isolated from mouse and human cardiac tissues. m6A-related new protocols are described here. The rest of the methods are described in detail in the online-only Data Supplement.
PolyA + RNA Isolation From Human and Mouse LV
For human polyA + RNA, ≈100 mg of LV tissue was homogenized using multiple Ribonuclease (RNase)/Deoxyribonuclease (DNase)-free 2-mL lysing matrix tubes (MP Biomedicals) using a tissue homogenizer. For mouse polyA + RNA isolation, 3 to 4 sham or 5 to 6 myocardial infarction (MI) (infarct) LV tissues were pooled to achieve ≈100 mg tissue and homogenized as described for human samples. RNA was extracted using the miRNAeasy kit (Qiagen) as recommended by the manufacturer (more detail in the online-only Data Supplement). For polyA + RNA isolation, ≈150 μg of total RNA in 500 mL of RNase-free water from each LV extract was then prewarmed in a 65°C heating block for 10 minutes before adding Biotinylated-Oligo(dT) probe for hybridization (Promega). After allowing Oligo(dT) hybridization to PolyA + tail for 10 minutes in room temperature, Streptavidin-Paramagnetic Particles (Promega) were added, and polyA + -containing RNA was isolated using magnetic capture of biotin-streptavidin conjugates. PolyA + RNA was then eluted in RNase-free water as recommended by the manufacturer's protocol. The isolation of polyA + RNA fraction was ensured by analyzing polyA + RNA in a bioanalyzer. PolyA + RNA was immediately quantified using a nanodrop spectrophotometer, and RNA samples were stored as aliquots at -80°C.
Quantification of m6A in Total and
PolyA + RNA
Column-purified total RNA (miRNeasy, Qiagen) or OligodTenriched polyA + RNA (Promega) was used for quantification of m6A modification. For quantification of m6A in human, pig, and mouse failing or nonfailing ischemic LV, we used a previously described antibody-based m6A capture and colorimetric quantification method (P-9005, EpiGentek). 18, 19 For both total or polyA + RNA, 200 ng of RNA per sample was transferred to corresponding wells in a 96-well plate. All samples were performed in duplicate. Both negative and positive controls, and a standard curve in the range of 0.02 to 1 ng of m6A, as well, were included as recommended by the manufacturer. In brief, after binding of RNA to wells, anti-m6A antibody was added and washed 3 to 4 times as recommended by the manufacturer's protocol. Antibody-bound m6A in RNA was detected by adding developer solution, and colorimetric quantification was performed subsequently by using a SpectraMax plus microplate reader. The percentage of m6A in RNA was calculated and compared with corresponding control samples and established as a percentage of m6A in total RNA.
Methylated RNA Immunoprecipitation and Next-Generation Sequencing (MeRIP-seq)
In brief, 200 μg of human or mouse total RNA was used. For mouse, at least 4 LVs per sham group and at least 6 LVs per MI group were pooled to achieve 200 μg of RNA (RNA integrity number >8). Both human and mouse total RNA were then isolated for polyA + RNA (Promega) and RNA quantified. PolyA + RNA was then fragmented to ≈100-nucleotide-long fragments using RNA fragmentation buffer (Millipore Sigma). RNA fragmentation was ensured by bioanalyzer before proceeding to m6A-immunoprecipitation. Nonimmunoprecipitation RNA was stored from fragmented RNA for bioinformatics analysis. The remaining fragmented polyA + RNA was subjected to m6A-immunoprecipitation by using 5 μg of anti-m6A (17-10499, Millipore Sigma). 20 Antibody-bound m6A-modified RNAs were eluted in RNase-free water as recommended by the manufacturer's protocol. Immunopurified RNA was then precipitated overnight at -80°C, and samples were sent to the Weill Cornell Medical College Genomic Core facility (New York) for library construction. The usual steps involving polyA + enrichment and fragmentation during library construction were omitted, and libraries were constructed using RNA-seq TruSeq-stranded mRNA type. Libraries were sequenced by the Illumina HiSeq 2500 platform (Illumina) as 50-bp single reads. Unaligned reads were mapped to the mm10 reference genome using STAR v2.5.3a at default settings. For each condition, total methylated (m6A) RNA immunoprecipitation (MeRIP) reads per transcript were calculated for reads that fully overlapped with a given feature, and were normalized to total nonimmunoprecipitation reads per corresponding transcript. This ratio was normalized to corresponding sham values, and was defined as fold change. Differential peak analyses of m6A MeRIP-Seq data ORIGINAL RESEARCH ARTICLE sets were performed by using a modification of the exomePeak R/Bioconductor package to compare the ratio of the absolute number of MeRIP reads with nonimmunoprecipitation reads at a given peak between 2 conditions. To remove false-positive signaling in our differential methylation analysis, we have used the same input read threshold as recommended. 21 In other words, differential methylation between 2 conditions at a given peak was calculated as
FC

Bound non IP Bound non IP
where FC denotes fold change; Bound 1 and Bound 2 are the number of reads within a peak for the MeRIP samples for conditions 1 and 2, respectively; and non-IP 1 and non-IP 2 are the number of reads within a peak for the nonimmunoprecipitation samples for conditions 1 and 2, respectively. In our differential methylation analysis, fold changes of ±2 between 2 conditions at a given peak and a formal test with proper false discovery rate control (false discovery rate <0.05) were included and considered significant. The data have been deposited in the GEO repository with the accession number GSE112789. MeRIP tracks were visualized with Integrative Genomics Viewer, using filtered (see above for filtering methods) .bam files from each group at select loci.
For MeRIP-quantitative polymerase chain reaction, immunopurified RNA was purified, and first-strand cDNA synthesis was performed as described in the online-only Data Supplement. Enrichment of mRNA in m6A-immunopurified samples was expressed relative to 18S rRNA in bound samples and expressed as fold change between groups. Taqman primers were used for testing m6A enrichment within transcripts; for RYR2 (Hs00181461_m1), ATP2A2/SERCA2A (Hs00544877_m1).
The DAVID bioinformatics database was used for gene ontology analysis on significant differentially methylated MeRIP peaks (defined above). Gene ontology classification was performed at default settings.
Statistical Methods
Data are shown as mean ± SEM unless otherwise stated. Oneway ANOVA was used to determine statistical significance for experiments with >2 groups followed by Bonferroni post hoc tests. Figures with ANOVA analysis where applicable are indicated in corresponding figure legends. Comparisons between 2 groups were performed using GraphPad software with an unpaired Student t test. P values <0.05 were considered statistically significant and assigned in individual figures.
RESULTS
Increased m6A in RNA in Human, Pig, and Mouse Failing Hearts
We quantified m6A levels in RNA extracted from failing human (both ischemic and nonischemic) and pig and mouse (post-MI ischemic) hearts, and compared them with m6A in nonfailing human and sham surgical controls, respectively. We detected significantly elevated levels of m6A in both total and polyA + RNA extracted from human, pig, and mouse failing LV explants in comparison with nonfailing or sham ( Figure 1A through 1C) . The increase in m6A in total RNA was observed as early as 1 week post-MI in mice ( Figure 1C ) and 2 weeks post-MI in pigs ( Figure 1B) . We also observed a sustained increase in m6A in both total and polyA + RNA in chronic phases of MI-induced heart failure in both mouse and pig ischemic LVs measured at 4 weeks and 20 weeks, respectively (Figure 1B and 1C) . It is interesting to note that the increase in m6A appeared to be confined only to the infarct and peri-infarct regions, because it was not detected in the noninfarct (remote) LV tissues in both pigs and mice in all time points investigated ( Figure 1D and 1E). These results provide strong evidence of increases in m6A in RNA in chronic heart failure conditions in humans, which were conserved across species in swine and mouse.
Decreased FTO Expression in Human and Mouse Failing Hearts
To identify regulators of elevated m6A in failing hearts, we measured expression levels of several known RNAs and proteins associated with m6A methylation (writers, such as METTL3, METTL4, and METTL14, and their regulatory subunit, WTAP) and demethylation (erasers, such as FTO and ALKBH5) 5 in human and mouse hearts. Western blot and quantitative reverse transcription polymerase chain reaction data revealed that expression of FTO (for human; for mouse/rat, Fto) was significantly decreased in failing LV explants from human and mouse, both at the RNA and the protein levels in comparison with their respective controls (Figure 2A through 2F) . The postischemic decrease of Fto was detected as early as 4 hours post-MI in mice hearts, and the decrease in Fto mRNA and protein levels consistently correlated with increased m6A at 1 week and 4 weeks post-MI in mouse ( Figure 2D through 2F) . Moreover, the transient, inconsistent increase or decrease of other m6A writers and erasers ( Figure 2G and Figure  IA through ID in the online-only Data Supplement) could not fully explain the aberrant and sustained increase in m6A in the failing hearts. It is interesting to note that, among all the m6A writers and erasers studied, FTO had the highest baseline expression both at the RNA and protein levels in healthy human (Figure 2A and Figure IIA and IIB in the online-only Data Supplement) and no-surgery mouse ( Figure IIC through IIE in the online-only Data Supplement) LV tissues. Collectively, these data established that ischemia-induced loss of FTO could be an important molecular hallmark that may explain the increase in m6A in human and mouse failing hearts.
Fto-Dependent m6A Demethylation Regulates Intracellular Ca 2+ and Sarcomere Dynamics in Cardiomyocytes
To investigate the role of Fto in cardiomyocytes and to determine if Fto is a direct regulator of m6A, we estab-
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lished cell culture models with loss of Fto using small interfering RNA to Fto (siFto) and gain of Fto using adenovirus-carrying Fto (adFto) in isolated adult rat primary cardiomyocytes and compared them with small interfering RNA control (siCtrl) and adenovirus with empty cytomegalovirus promoter (adnull) controls, respectively ( Figure 3A and Figure IIIA and IIIB in the online-only Data Supplement). It is interesting to note that the expression of Fto inversely correlated with the level of m6A in total RNA in primary myocytes ( Figure 3A and 3B). Similar to ischemic mouse and human hearts, primary cardiomyocytes subjected to hypoxia had decreased Fto expression ( Figure 3A ) and increased m6A in RNA ( Figure 3B ). Overexpressing Fto in cardiomyocytes cultured under hypoxia reversed the hypoxia-induced aberrant increase in m6A in RNA ( Figure 3B ), suggesting that Fto is a key regulator of m6A in cardiomyocytes. However, m6A and Fto levels in adult rat primary nonmyocytes subjected to hypoxia remained unchanged in comparison with normoxic nonmyocytes ( Figure IIIC and IIID in the onlineonly Data Supplement), suggesting that myocytes are more responsive to Fto-dependent m6A dysregulation than nonmyocytes. In the same line, we found that primary cardiomyocytes isolated from healthy human LV have significantly higher expression of FTO than primary nonmyocytes from the same hearts ( Figure IV in the online-only Data Supplement). In addition, the human ventricular myocyte cell line, but not human cardiac fibroblasts or endothelial cells in culture, had significantly lower FTO mRNA expression under hypoxia stress (Figure IV in the online-only Data Supplement). Together, these data indicate that myocytes regulate FTO expression under hypoxic stress.
To investigate the functional significance of Fto-modulated m6A in cardiomyocyte contractile function in vitro, we measured pacing-induced calcium (Ca 2+ ) dynamics and contractile properties in Fto-modulated primary cardiomyocytes cultured under normoxic and hypoxic conditions. It is remarkable that siFto-treated myocytes with higher m6A levels exhibited a significantly increased number of arrhythmic events in comparison with siCtrl cardiomyocytes ( Figure 3C and 3D) , supporting an earlier observation that a decrease in Fto-demethylase activity leads to proarrhythmic remodeling and altered ventricular repolarization in Fto-deficient mice hearts. 16 However, hypoxia-induced cardiomyocyte dysfunction was significantly improved by overexpressing Fto in hypoxic cardiomyocytes that resulted in improved Ca 
Contractile Transcripts Hypermethylated in Failing Hearts Are Demethylated by Fto Overexpression
To identify the m6A demethylating targets of Fto in the transcriptome, we performed immunoprecipitation of m6A-modified RNA (MeRIP) followed by sequencing from sham, MI, aavgnp-MI, and aavFto-MI mouse LV tissues from the peri-infarct area ( Figure XII in the online-only Data Supplement). 4, 22 Differential expression of individual transcripts across conditions can affect perceived m6A enrichment in MeRIP; therefore, to identify differential m6A modifications across conditions independent of varying transcription, 4,21 we normalized MeRIP reads to corresponding nonimmunoprecipitation reads within each condition by using a 
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( Figure XIIIA in the online-only Data Supplement). It also suggests that Fto demethylates a subset of transcripts ( Figure 6B ) that are largely associated with cardiac hypertrophy, muscle contraction, filament sliding, and sarcomere organization ( Figure 6C and Tables I through VIII in the online-only Data Supplement). MeRIP-seq maps of individual transcripts show hypermethylated sites in MI in comparison with sham for several Ca 2+ and contractile transcripts such as Nppa, Myh7, Serca2a, Ryr2, and myocardium-specific long noncoding RNAs Mhrt and Chast, as well, which were demethylated in aavFto-MI ( Figure 6D and Tables III and IV in the online-only Data Supplement). In addition, our MeRIP-seq identified that FTO overexpression resulted in the regulation of angiogenic and fibrotic (extracellular matrix) pathways (Tables IV and VIII in the online-only Data Supplement). Our results confirm prior observations of Serca2a methylation in 3T3L1 preadipocytes and in HeLa cells in response to heat shock. [23] [24] [25] Polymerase chain reaction analyses of MeRIP-enriched RNA from human LV tissues confirmed that Ca 2+ -handling transcripts SERCA2a and RYR2 were hypermethylated in the failing human hearts ( Figure 7A ). Consistent with this, SERCA2a mRNA was demethylated when Fto was overexpressed in human myocytes ( Figure 7B and Figure XIIIB and XIIIC in the online-only Data Supplement), resulting in increased SERCA2a mRNA expression ( Figure 7C ). Indeed, these effects were translated to mouse post-MI in FTO-overexpressing Figure 7D and 7E) . Demethylation of SERCA2a mRNA and its association with increased mRNA levels could be a result of FTO increasing the stability of SERCA2a mRNA and possibly of other contractile mRNAs 26, 27 or a cotranscriptional regulation by FTO. 19 Our in vivo data showing increased Serca2a protein expression in aavFto-MI and adFto-MI mice corroborated our findings ( Figure 7F ). Collectively, our MeRIP analysis confirmed transcriptome-wide hypermethylation post-MI, demethylation with Fto gene delivery, and Fto targeting a subset of mRNAs involved in positive regulation of calcium and contractile function during cardiac remodeling.
Our results have uncovered dysregulation of m6A as an important molecular hallmark of postischemic cardiac remodeling and a novel layer of gene regulation at the RNA level in heart failure.
DISCUSSION
In this study, we have found compelling in vitro, in vivo, and translational evidence demonstrating an important role for FTO in cardiomyocyte and cardiac function under physiological, pathological, and reparative conditions. We have identified FTO as a key myocardial demethylase that regulates cardiac m6A and provided a novel characterization of FTO-dependent m6A in cardiac contractile function. FTO expression is downregulated in heart failure, leading to an aberrant increase in global cardiac m6A as well as m6A in selective contractile transcripts, leading to their decreased protein expression. Loss of FTO resulted in anomalous calcium handling and sarcomere dynamics, resulting in the loss of contractile function in primary cardiomyocytes. It is interesting to note that forced expression of FTO in stressed hypoxic cardiomyocytes or failing murine myocardium attenuated ischemia-induced cardiac remodeling, loss of cardiac contractile protein expression, and loss of cardiac contractile function, demonstrating the therapeutic potential of FTO. By comparing the cardiac m6A maps of individual transcripts, we discovered that FTO selectively demethylates cardiac contractile transcripts such as SERCA2A, MYH6/7, RYR2, and many 
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others, improving their mRNA and protein expression. We have further shown that the cardioprotective mechanism of FTO is mediated by selective demethylation of cardiac contractile transcripts under ischemia, which increases mRNA stability and protein expression. 10, 28, 29 Our MeRIP-seq pathway analyses indicate that FTO acts on selective cardiac pathways, such as those relevant to sarcomere organization, myofibril assembly, calcium handling, and contractility ( Figure 6C , Tables III, IV , VII, and VIII in the online-only Data Supplement). In addition, it also acts on pathways related to angiogenesis and fibrosis (extracellular matrix) and on long noncoding RNAs including Chast or Mhrt, which are implicated in fibrosis and hypertrophy ( Figure 6D , Tables IV and VIII in the online-only Data Supplement). In addition to restoring contractile protein expression such as SERCA2A, we provided experimental evidence that FTO overexpression decreased cardiac fibrosis and enhanced angiogenesis in the ischemic myocardium. Our study demonstrates the functional importance of FTOdependent cardiac m6A methylome in cardiac contraction, fibrosis, and angiogenesis during heart failure and provides robust mechanistic insights into the therapeutic potential of FTO ( Figure 8 ). FTO is a dioxygenase that oxidatively demethylates m6A-containing mRNAs. 12 Thus, the enzymatic activity of FTO may be expected to decrease under hypoxic or ischemic conditions independent of its expression levels. It is interesting to note that we also found that both hypoxia in primary cardiomyocytes and ischemia in mouse hearts have reduced expression of FTO, both at the protein and the RNA level. There could be several direct and indirect mechanisms for FTO downregulation under hypoxic/ischemic stress, including hypoxia-inducible microRNA binding. We identified binding sites in FTO mRNA for several hypoxia-inducible cardiac microRNAs such as miR-21, miR-24, miR-488, miR-224, miR-489, and miR-199:miR-214 cluster, 30, 31 which are known to be upregulated in heart failure. A direct role for these miRs could reveal upstream pathways of FTO regulation in heart failure. Both transcriptional and posttranscriptional suppression of FTO, and hypoxia-induced reduction in FTO activity, as well, support our in vitro and in vivo observations of the increase in m6A on FTO silencing, in hypoxia, and in heart failure.
By modulating FTO expression through silencing or overexpression in isolated primary cardiac myocytes, we have demonstrated that FTO is a key contributor of global m6A levels. Furthermore, FTO expression inversely correlates with m6A, and FTO-dependent m6A is a novel and positive regulator of cardiomyocyte and cardiac contractile function. In this line, a recent study investigated FTO in myoblast differentiation and found that FTO depletion interfered with myogenic differentiation, highlighting that FTO is required for myogenesis. 28 These data implicate FTO as an important regulator of muscle physiology.
Because m6A demethylation in a single-stranded nuclear RNA is the only known primary function of FTO, we attribute the effects of FTO alteration directly to changes in m6A in the target transcripts. Nevertheless, we do not rule out FTO-dependent N 6 ,2ʹ-Odimethyladenosine (m6A m ) demethylation, 32 long noncoding RNA demethylation or other indirect effects resulting from FTO (m6A)-regulated transcriptional coregulatory networks or microRNA expression. Moreover, in addition to FTO downregulation, we detected elevated levels of writer proteins such as METTL4/14 in human and Mettl14 in mouse failing hearts, suggesting that these writers possibly also contribute to the increased m6A in failing hearts. Whether these writers compete with FTO to target similar subsets and locations of transcripts or function in a mutually exclusive manner needs to be investigated. It is interesting to note that the increase in transcriptome-wide m6A was significant only at 1 week post-MI, although FTO expression was downregulated as early as 4 hours post-MI. This discrepancy in transcriptome-wide m6A increase could be explained by the upregulation of another closely related m6A demethylase, ALKBH5, at 4 hours and 1 day post-MI. An increase in ALKBH5 could offset the increased m6A resulting from the loss of FTO at both 4-hour and 1-day time points. This claim was corroborated by the observation that ALKBH5 protein expression returned to normal levels comparable to control hearts at 1 week and 4 weeks post-MI, effectively increasing global m6A levels at those time points, primarily resulting from the loss of FTO and, in part, from the transient increase in m6A writers. Because m6A is dynamically regulated, the interplay between writer, eraser, and reader proteins could be important regulating the protein expression during cardiac remodeling and regeneration, and, therefore, needs to be determined.
Transcriptome-wide m6A profiling of failing mouse hearts indicated hypermethylation of several transcripts encoding cardiac contractile proteins. Previous studies have shown that hypermethylated transcripts are less stable and negatively regulate translation. 6, 33, 34 We consistently detected hypermethylation in contractile transcripts, including MYH6, RYR2, SERCA2a, etc, whose expressions are known to be significantly decreased in human and mouse failing hearts. This finding corroborated our in vitro data with FTO depletion or hypoxic treatment increased the m6A that resulted in aberrant cardiomyocyte calcium handling and contractile function. However, forced expression of FTO in mouse failing hearts resulted in demethylation of contractile transcripts (SERCA2a), bringing their m6A to a near-normal level. This resulted in significant improvement in contractile protein (SERCA2a) expression and cardiac function as demonstrated by improved ejection fraction and frac- In addition to positively regulating contractile protein expression, Fto-dependent demethylation could also regulate noncontractile protein expression in cardiomyocytes, in line with a recent study reporting that FTO-dependent m6A demethylation negatively regulated mRNA and protein expression in acute myeloid leukemia cancer cells. 9 In our study, we did not find any significant effect of hypoxia on FTO expression and on global m6A levels in nonmyocytes in vitro. However, we cannot not rule out altered m6A sites within individual transcripts under A, Healthy heart with physiological FTO and m6A levels. B, Failing heart with decreased FTO, increased m6A, increased contractile mRNA degradation, and dysfunctional myofilament. C, Fto rescued failing heart with attenuated m6A and restored contractile protein expression and myofilament. FTO indicates fat-mass and obesity associated protein; and m6A, N 6 -methyladenosine.
hypoxia that may have functional roles. It is interesting to note that our MeRIP sequencing analysis revealed that, in addition to contractile pathways, FTO overexpression regulates important noncontractile pathways as well, including tissue morphogenesis, angiogenesis, extracellular matrix organization, fibrosis, and cell growth in murine MI hearts. These MeRIP data were supported by experimental observations of enhanced angiogenesis, and reduced scar size in the FTO-overexpressed murine MI hearts, as well. Collectively, these data suggest that FTOdependent m6A regulates both contractile and noncontractile pathways in murine myocardium. Whether these noncontractile phenotypes are direct functional effects of m6A on noncontractile transcripts and pathways or indirect effects of m6A-dependent transcripts and pathways needs further investigation. Our analysis of hypermethylated transcripts in failing hearts revealed pathways involving heart rate and muscle contraction, which have decreased expression at the mRNA and proteins level in failing hearts. It is interesting to note that our MeRIP analysis also detected several transcripts whose m6A levels were not affected by myocardial infarction surgery or by FTO overexpression, whereas their protein expressions are known to be differentially regulated in failing mouse and human hearts. This observation possibly indicates site-specific demethylation of the transcript that is not reflected in the overall m6A quantification, downstream regulation of mRNA transport and processing by FTO, or additional unknown mechanisms of FTO function. 35 Increased or decreased expression of proteins as a result of FTO-dependent mRNA demethylation could be regulated by mRNA stability, 19 ,24 degradation, 6 and the rate of translation. 26 In fact, m6A has been shown to have both stimulatory 24, 26 and inhibitory 19, 36 effects on the translation dynamics. The precise effect of m6A on translation may depend on the specific 5ʹ and 3ʹ location of m6A within the transcript. 19, 24, 37 The site-specific m6A maps of transcripts and the role of site-specific methylation in translation warrant further investigation. m6A has been shown to regulate stem cell renewal 38 ; however, direct evidence for m6A in tissue regeneration and repair has not been established. Here, we identified a novel role for m6A and myocardial m6A demethylase, FTO, in regulating cardiac tissue repair and contractile function after myocardial ischemia. In addition to the sustained expression of FTO using the AAV9 vector, we detected significant beneficial effects of transiently expressed FTO-delivered postischemia using adFTO. This indicates that FTO is therapeutic, and FTO-mediated m6A demethylation can induce homeostatic protein expression, resulting in improved cardiac function. It is notable that Fto levels were downregulated as early as 4 hours post-MI in mouse. Adenovirus-mediated gene delivery, which maximizes FTO expression in 2 days and provides stable FTO expression for about a week, could improve cardiac homeostasis and function following the initial remodeling phase induced by MI. This transient FTO overexpression following the initial remodeling phase, and sustained FTO overexpression using AAV9, as well, suggests that FTO-mediated benefits could be a result of both protective and reparative mechanisms of FTO. However, further studies are warranted to specifically address the precise mechanisms of FTO-mediated beneficial action. These data strongly suggest a potential therapeutic application of FTO in the treatment of postischemic heart failure. FTO or FTO mimics can be an interesting next-generation therapeutics that can target and simultaneously improve the expression of several key contractile proteins in the heart. Furthermore, there is an ongoing debate for a role of FTO in obesity and body weight with several studies reporting either positive or negative association for FTO with body mass. 39, 40 We did not observe significant differences in body weight between the control and FTO-overexpressing mice. Although we show the cardioprotective function of FTO, a better understanding of the effect of FTO in body mass is required to take advantage of its clinical potential for the treatment of human heart failure. Together, our data provide proof of principle that, given the functional importance of FTO in cardiac homeostasis and myocardial repair, targeting FTO signaling may represent a promising therapeutic strategy to treat heart failure. Our findings on the dynamic nature of the cardiac m6A-epitranscriptome will lead to a deeper understanding of the mechanism of cardiac remodeling on the one hand and innovative therapeutic interventions on the other.
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